Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche's Tecentriq Positive But Not Perfect In IMpower130 First-line Lung Cancer Study

Executive Summary

Combination with Abraxane demonstrates an overall survival benefit on top of progression-free survival, but Merck's competing Keytruda has set a high benchmark for first-line metastatic lung cancer.

You may also be interested in...



EU OK To Tecentriq-Avastin Combo In NSCLC Includes EGFR-Mutant, ALK-Positive Patients

EU approval of Tecentriq and Avastin together with chemo for the first-line treatment of metastatic non-squamous NSCLC is a positive advance for Roche, but analysts say the combo has a long way to go still to catch up with Merck & Co’s Keytruda combination.  

Keeping Track: FDA's Review Actions Carry On During Shutdown

The latest drug development news and highlights from our US FDA Performance Tracker.

Mystic Miss Not Make Or Break For Imfinzi

While the failure of AstraZeneca's Imfinzi in the MYSTIC trial for stage IV lung cancer is a blow, it is not going to have much of an effect on the potential for the company which has carved out a sizeable niche for the drug in stage III NSCLC.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124039

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel